Mutagen sensitivity: Enhanced risk assessment of squamous cell carcinoma

European Journal of Cancer Part B: Oral Oncology

Volumn 32, Issue 6, 1996, Pages 367-372

  Cloos, J ^a   Reid, C B A ^a   Snow, G B ^a   Braakhuis, B J M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Head and neck cancer; Mutagen; Oral cancer

Indexed keywords

MUTAGENIC AGENT;

HEAD AND NECK CANCER; HUMAN; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; DISEASE SUSCEPTIBILITY; HEAD AND NECK NEOPLASMS; HUMANS; MUTAGENICITY TESTS; NEOPLASMS, MULTIPLE PRIMARY; RISK ASSESSMENT;

EID: 0030292301     PISSN: 09641955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0964-1955(96)00019-X     Document Type: Review

References (78)

1. 1. Muir C, Weiland L. Upper aerodigestive tract cancers. Cancer 1995, 75, 147-153.
2. 2. Barnes L, Verbin RS, Gnepp DR. Disease of the nose, paranasal sinuses and nasopharynx. In Barnes L, ed. Surgical Pathology of the Head and Neck. New York, Marcel Dekker, 1985, 403-451.
3. 3. Yokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. New Engl J Med 1993, 328, 184-193.
4. 4. Blitzer PH. Epidemiology of head and neck cancer. Semin Oncol 1988, 15, 2-9.
5. 5. De Vries N, Magnitude of the problem.. In de Vries N, Gluckman JL, eds. Multiple Primary Tumors in the Head and Neck. Stuttgart, George Thieme 1990, 1-29.
6. 6. Slaughter DP, Southwick HW, Smejkel W. "Field cancerization" in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953, 6, 963-968.
7. 7. Hittelman WN, Lee JS, Cheong N, Shin D, Hong WK. The chromosome view of "field cancerization" and multistep carcinogenesis, Implications for chemopreventive approaches. In Pastorino U, Hong WK, eds. Chemoimmuno Prevention of Cancer. Stuttgart, George Thieme 1991, 41-47.
8. 8. Snow GB. Follow-up in patients treated for head and neck cancer: how frequent, how thorough and for how long. Eur J Cancer 1991, 28, 315-316.
9. 9. Bongers V, Snow GB, De Vries N, et al. Second primary head and neck squamous cell carcinoma predicted by the glutathione S-transferase expression in healthy tissue in the direct vicinity of the first tumor. Lab Invest 1995, 73, 503-510.
10. 10. Copper MP, Braakhuis BJM, De Vries N, Van Dongen GAMS, Nauta JJP, Snow GB. A panel of biomarkers of carcinogenesis of the upper aerodigestive tract as potential intermediate endpoints in chemoprevention trials. Cancer 1993, 71, 825-830.
11. 11. Day GL, Blot WJ, Shore RE, et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst 1994, 86, 131-137.
12. 12. Kune GA, Field B, Watson LF, Cleland H, Merenstein D, Vitta L. Oral and pharyngeal cancer diet, smoking, alcohol, and serum vitamin-A and beta carotene levels-a case-control study in men. Nutr Cancer 1993, 20, 61-70.
13. 13. DeLuca LM. Retinoids and their receptors in differentiation, embryogenesis and neoplasia. FASEB J 1993, 5, 2924-2933.
14. 14. De Flora S, D'Agostini F, Izzotti A, Balansky R. Prevention by N-acetyl-cysteine of benzo(a)pyrene clastogenicity and DNA adducts in rats. Mutat Res 1991, 250, 87-93.
15. 15. Izzotti A, Balansky R, Scatolini L, Rovida A, Deflora S. Inhibition by N-acetylcysteine of carcinogen-DNA adducts in the tracheal epithelium of rats exposed to cigarette smoke. Carcinogenesis 1995, 16, 669-672.
16. 16. Albini A, Dagostini F, Giunciuglio D, Pagheri I, Balansky R, Deflora S. Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int J Cancer 1995, 61, 121-129.
17. 17. Moon RC, McCormick DL. Metha RG. Inhibition of carcinogenesis by retinoids. Cancer Res 1983, 43, 2469s-2475s.
18. 18. Hill DL, Grubb CJ. Retinoids and cancer prevention. Annu Rev Nutr 1992, 12, 161-181.
19. 19. Shalinsky DR, Bischoff ED, Gregory ML, et al. Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (Line 1483) in athymic nude mice. Cancer Res 1995, 55, 3183-3191.
20. 20. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors in squamous cell carcinoma of the head and neck. New Engl J Med 1990, 323, 975-801.
21. 21. Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of 2nd primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck -long-term follow-up. J Natl Cancer Inst 1994, 86, 140-141.
22. 22. De Vries N, Zandwijk N van, Pastorino U. Chemoprevention in the management of oral cancer: EUROSCAN and other studies. Oral Oncol 1992, 28B, 153-157.
23. 23. Alfa-tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New Engl J Med 1994, 330, 1029-1035.
24. 24. Morse MA, Stoner GD. Cancer chemoprevention: Principles and prospects. Carcinogenesis 1993, 14, 1737-1746.
25. 25. Lippman SM, Spitz MR, Trizna Z, Benner SE, Hong WK. Epidemiology, biology, and chemoprevention of aerodigestive cancer. Cancer 1994, 74, 2719-2725.
26. 26. Larsson PA, Edstrom S, Westin T, Nordkvist A, Hirsch JM, Vahlne A, Reactivity against herpes simplex virus in patients with head and neck cancer. Int J Cancer 1991, 49, 14-18.
27. 27. Fouret P, Martin F, Flahault A, Saintguily JL. Human papillomavirus infection in the malignant and premalignam head and neck epithelium. Diagn Mol Pathol 1995, 4, 122-127.
28. 28. Muscat JE, Wynder EL. Tobacco, alcohol, asbestos, and occupational risk factors for laryngeal cancer. Cancer 1992, 69, 2244-2251.
29. 29. Maier H, Dietz A, Gewelke U, Heller WD. Occupational exposure to hazardous substances and the risk of cancer in the area of the mouth cavity, oropharynx, hypopharynx and larynx. A case-control study. Laryngol Rhinol Otol 1991, 70, 93-98.
30. 30. La Vecchia C. Diet and human oral carcinoma in Europe. Oral Oncol, Eur J Cancer 1993, 29B, 17-22.
31. 31. Zheng W, Blot WJ, Diamond EL, et al. Serum micronutnents and the subsequent risk of oral and pharyngeal cancer. Cancer Res 1993, 53, 795-798.
32. 32. Garewal HS. Beta-carotene and vitamin E in oral cancer prevention. J Cell Biochem (Suppl) 1993, 17F, 262-269.
33. 33. Wynder EL, Hoffmann D. Smoking and lung cancer: scientific challenges and opportunities. Cancer Res. 1994, 54, 5284-5295.
34. 34. Kato I, Nomura MY. Alcohol in the aetiology of upper aerodigestive tract cancer. Oral Oncol, Eur J Cancer 1994, 30B, 75-81.
35. 35. Ng SKC, Kabat GC, Wynder EL. Oral cavity cancer in nonusers of tobacco. J Natl Cancer Inst 1993, 85, 743-745.
36. 36. Spitz MR, Fucger JJ, Goepfert H, Hong WK, Newell GR. Squamous cell carcinoma of the upper aerodigestive tract. Cancer 1988,61, 203-208.
37. 37. Maier H, Dietz A, Gewelke U, Heller WD, Weidauer H. Tobacco and alcohol and the risk of head and neck cancer. Clin Invest 1992, 70, 320-327.
38. 38. Harris CC. Chemical and physical carcinogenesis: Advances and perspectives for the 1990s. Cancer Res 1991, 51, 5023s-5044s.
39. 39. Hlavica P. Regulatory mechanisms in the activation of nitrogenous compounds by the cytochrome P-450 isozymes. Drug Metab Rev 1994, 26, 325-348.
40. 40. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure-a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase m1 (GSTMl) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993, 85, 1159-1164.
41. 41. Nakajima T, Elovaara E, Anttila S, et al. Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer. Carcinoogenesis 1995, 16, 707-711.
42. 42. Gatti RA, McConville CM. Sixth international workshop on Ataxia telangiectasia. Cancer Res 1994, 54, 6007-6010.
43. 43. Hecht F, Hecht BK. Cancer in ataxia telangiectasia patients. Cancer Genet Cytogenet 1992, 46, 9-19.
44. 44. Swift M, Chase CL, Morrell D. Cancer predisposition of ataxia telangiectasia heterozygotes. Cancer Genet Cytogenet 1990, 46, 21-27.
45. 45. Cortessis V. Linkage analysis of DRD2, a marker linked to the ataxia-telangiectasia gene, in 64 families with premenopausal bilateral breast cancer. Cancer Res 1993, 53, 5083-5086.
46. 46. Lehmann AR, Stevens S. The response of ataxia telangiectasia cells to bleomycin. Nucleic Acids Res 1979, 6, 1953-1960.
47. 47. Taylor AMR, Byrd PJ, Mcconville CM, Thacker S. Genetic and cellular features of ataxia telangiectasia. Int J Radiat Biol 1994, 65, 65-70.
48. 48. Gantt R, Parhad R, Price FM, Sanford KK. Biochemical evidence for deficient DNA repair leading to enhanced G2 chromatid radiosensitivity and susceptibility to cancer. Radiat Res 1986, 108, 117-126.
49. 49. Scott D, Spreadborough A, Levine E, Roberts SA. Genetic predisposition in breast cancer. Lancet 1994, 344, 1444.
50. 50. Hsu TC. Genetic instability in the human population: a working hypothesis. Hereditas 1983, 98, 1-9.
51. 51. Pryar WA. Cigarette smoke and the involvement of free radical reactions in chemical carcinogenesis. Ann NY Acad Sci 1982, 393, 1-22.
52. 52. Hsu TC, Cherry LM, Samaan NA. Differential mutagen susceptibility in cultured lymphocytes of normal individuals and cancer patients. Cancer Genet Cytogenet 1985, 17, 307-313.
53. 53. Hsu TC. Genetic predisposition to cancer with special reference to mutagen sensitivity. In Vitro Cell Devel Biol 1987, 23, 591-603.
54. 54. Hsu TC, Johnston DA, Cherry LM, et al. Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. Int J Cancer 1989, 43, 403-409.
55. 55. Schantz SP, Hsu TC. Mutagen-induced chromosome fragility within peripheral blood lymphocytes of head and neck cancer patients. Head Neck 1989, 11, 337-342.
56. 56. Cloos J, Braakhuis BJM, Steen I, et al. Increased mutagen sensitivity in heed and neck squamous cell carcinoma patients, particularly those with multiple primary tumors. Int J Cancer 1994, 56, 816-819.
57. 57. Spitz MR, Wu X, Hsu TC. Mutagen sensitivity and wood dust exposure in lung cancer: a case-control analysis. Proc Am Assoc Cancer Res 1995, 36, 280.
58. 58 Hagmar L, Brogger A, Hansteen I, et al. Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosomal damage. Cancer Res, 1994, 54, 2919-2922.
59. 59. Li S, Lin J. Differential bleomycin susceptibility in cultured lymphocytes of fragile X patients and normal individuals. Human Genet 1990, 85, 267-271.
60. 60. Ning Y, Yongshan Y, Pai GS, Gross AJ. Heterozygote detection through bleomycin-induced G2 chromatid breakage in dyskeratosis congenital families. Cancer Genet Cytogenet 1992, 60, 31-34.
61. 2 chromatin radiosensitivity in predisposition to cancer. Int J Radiol Biol 1989, 55, 963-981.
62. 62. Knight RD, Parshad R, Price FM, Tarone RE, Sanford KK. X-ray-induced chromatid damage in relation to DNA repair and cancer incidence in family members. Int J Cancer 1993, 54, 589-593.
63. 63. Liang JC, Pinkel DP, Bailey NM, Trujillo JM. Mutagen sensitivity and cancer susceptibility. Report of a cancer prone family. Cancer 1989, 64, 1474-1479.
64. 64. Bondy ML, Spitz MR, Halabi S, et al. Association between family history of cancer and mutagen sensitivity in upper aero-digestive tract cancer patients. Cancer Epidemiol Biomarken & Prev 1993, 2, 103-106.
65. 65. Schantz SP, Hsu TC, Ainslie N, Moser RP. Young adults with head and neck cancer express increased susceptibility to mutagen-induced chromosome damage. JAMA 1989, 262, 3313 3315.
66. 66. Hsu TC, Spits MR, Schantz SP. Mutagen sensitivity: a biological marker of cancer susceptibility. Cancer Epid Biomarkers & Prev 1991, 1, 83-89.
67. 67. Schantz SP, Spitz MR, Hsu TC. Mutagen sensitivity in patients with head and neck cancers: a biological marker for risk of multiple primary malignancies. J Natl Cancer Inst 1990, 82, 1773-1775.
68. 68. Spitz MR, Hoque A, Trizna Z, et al. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst 1994, 86, 1681-1684.
69. 69. Dave BJ, Hsu TC, Hong WK, Pathak S. Nonrandom distribution of mutagen-induced chromosome breaks in lymphocytes of patients with different malignancies, Int J Oncol 1994, 5, 733-740.
70. 70. Wu X, Spitz MR, Hsu TC. Survival of bleomycin-induced chromosomal lesions in cultured lymphocytes and its association with lung cancer. Proc Am Assoc Cancer Res 1995, 36, 275.
71. 71. Caporaso N, Goldstein A. Cancer genes: single and susceptibility: Exposing the difference. Pharmacogenetics 1995, 61, 480-484.
72. 72. Cloos J, Spitz MR, Schantz SP, et al. Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 1996, 88, 530-535.
73. 73. Spitz MR, Hsu TC, Wu X, Fueger JJ, Amos CI, Roth JA. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers & Prev 1995, 4, 99-103.
74. 74. West CML, Scott D, Peacock JH. Normal cell radiosensitivity: clinical application in predicting response to radiotherapy and cancer predisposition. Int J Radiat Biol 1994, 66, 231-234.
75. 75. Pollak MN. Correspondence Re: Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst 1995, 87, 458.
76. 76. Spitz MR, Liang JC, Strom S, King TM, Hsu TC. Response to correspondence. J Natl Cancer Inst 1995, 87, 458.
77. 77. Olden K. Mutagen hypersensitivity as a biomarker of genetic predisposition to carcinogenesis. J Natl Cancer Inst 1994, 86, 1660-1661.
78. 78 Hecht SS. Environmental tobacco smoke and lung cancer: the emerging role of carcinogen biomarkers and molecular epidemiology. J Natl Cancer Inst 1994, 86, 1369-1370.